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Abstract 
Somatostatin acts at five G protein-coupled receptors, sst1-sst5. In mouse ischemic retinas, the over-
expression of sst2 (as in sst1 knock-out mice) results in reduction of cell death and glutamate 
release. Here, we reported that, in wild-type retinas, somatostatin, the multireceptor ligand
pasireotide and the sst2 agonist octreotide decreased ischemia-induced cell death and that octreotide 
also decreased glutamate release. In contrast, cell death was increased by blocking sst2 with 
cyanamide. In sst2 over-expressing ischemic retinas, somatostatin analogues increased cell death, 
and octreotide also increased glutamate release. To explain this reversal of the anti-ischemic effect 
of somatostatin agonists in the presence of sst2 over-expression, we tested sst2 desensitisation due to 
internalisation or altered receptor function. We observed that: i) sst2 was not internalised, ii) among 
G protein-coupled receptor kinases (GRKs) and regulators of G protein signalling (RGSs), GRK1 
and RGS1 expression increased following ischemia, iii) both GRK1 and RGS1 were down-
regulated by octreotide in wild-type ischemic retinas, iv) octreotide down-regulated GRK1 but not 
RGS1 in sst2 over-expressing ischemic retinas. These results demonstrate that sst2 activation 
protects against retinal ischemia. However, in the presence of sst2 over-expression sst2 is 
functionally desensitised by agonists, possibly due to sustained RGS1 levels.
Key words: somatostatin receptors, cell death, glutamate release, G protein-coupled receptor 
kinases, regulators of G protein signalling
Running title: Somatostatin analogues in ischemic retinas
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Introduction
The primary cause of neuronal death in retinal diseases is ischemia, a condition that can be 
considered a final common pathway for injury in different retinal pathologies (Quigley et al. 1985; 
Quigley et al. 1995; Levin and Louhab 1996; Osborne et al. 1999; Barber 2003; Osborne et al.
2004). Glutamate excitotoxicity, occurring during retinal ischemia (Osborne et al. 2004), is likely to 
be a major cause of neuronal damage following an ischemic insult (Lipton 1999; Won et al. 2002; 
Arundine and Tymianski 2003; Camacho and Massieu 2006). The peptide somatostatin 
(somatotropin release-inhibiting factor, SRIF) plays important physiological roles, mostly 
inhibitory, which have formed the basis for the clinical use of SRIF compounds (Weckbecker et al.
2003; Cervia and Bagnoli 2007), and it may protect the retina against ischemia in a variety of retinal 
diseases (Cervia et al. 2008). SRIF binds to its 5 G protein-coupled receptors (GPCRs) which have 
been named sst1-sst5 (Hoyer et al. 1995) and are expressed in the retina (Bagnoli et al. 2003; 
Thermos 2003; Casini et al. 2005; Cervia et al. 2008). SRIF has a protective role in the retina, as 
shown in studies in guinea pigs and rats where sst2 agonists protect, to a certain extent, retinal cells 
from the ischemic damage (Celiker and Ilhan 2002; Mastrodimou et al. 2005; Mastrodimou et al.
2008). 
Recently, we have developed an in vitro model of the ischemic mouse retina, in which possible 
positive effects exerted by the somatostatinergic system against ischemia-induced damages have 
been investigated (Catalani et al. 2007). In particular, we demonstrated that an increased presence 
of functional sst2, consequent to the genetic deletion of sst1 (Dal Monte et al. 2003b; Casini et al.
2004), results in significant reduction of both ischemia-induced glutamate release and cell death, 
with respect to the wild type (WT) (Catalani et al. 2007). In the present study, we asked whether 
these protective effects observed in sst1 knock-out (KO) retinas could be modulated by agonists or 
antagonists of sst2. In particular, we expected that sst2 agonism on over-expressed sst2 (as in sst1 KO 
retinas) could result in significant potentiation of protection against ischemia, while a sst2 antagonist 
should abolish the protection given by sst2 over-expression. To investigate this, SRIF, the sst1,2,3,5
peptidyl agonist pasireotide, the sst2-preferring peptidyl agonist octreotide and the sst2-selective 
peptidyl antagonist cyanamide (Lewis et al. 2003; Nunn et al. 2003; Weckbecker et al. 2003) were 
added to the ischemic solution in order to determine the effects of the pharmacological modulation 
of SRIF receptors on retinal cell survival. In addition, the effects of octreotide on glutamate release 
were also studied. The data obtained in these experiments indicated the possibility that 
desensitisation of sst2 occurs in the presence of SRIF agonists. Desensitisation of GPCRs, defined 
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as a reduction in receptor signalling after pre-exposure to agonist, is a complex process that may 
involve either a loss of plasma membrane receptors due to receptor endocytosis or a reduced 
coupling efficiency between cell surface receptors and the intracellular signalling machinery. To 
study these mechanisms in our model, we i) investigated the possibility that octreotide causes 
internalisation of sst2 and, ii) investigated the expression of different regulators of GPCRs (Jean-
Baptiste et al. 2006; Moore et al. 2007; Ribas et al. 2007).
Materials and methods
Animals and in vitro treatments of retinas
Experiments were performed on mouse retinas of WT (C57BL/6 strain) and sst1 KO of both sexes 
at 6-8 weeks after birth (20-30 g body weight). The generation of sst1 KO mice has been detailed in 
Kreienkamp et al. (1999). To reduce genetic background variability, the sst1 null allele was 
backcrossed for five successive generations onto the C57BL/6J strain to produce N5 incipient-
congenic mice. Animals were kept in a regulated environment (23 ± 1°C, 50 ± 5% humidity) with a 
12 h light/dark cycle (lights on at 08.00 a.m.) with food and water ad lib. In all experiments, mice 
were anaesthetized by i.p. injection of Avertin (1.2% tribromoethanol and 2.4% amylene hydrate, 
0.02 ml/g body weight) and killed by cervical dislocation. Using published protocols (Catalani et al.
2007), the retinas were rapidly dissected and incubated for 1 h at 37°C in air-saturated phosphate-
buffered saline (PBS) containing 6 mM glucose in open vials (non ischemic, control conditions) or 
in N2-saturated PBS containing 250 mM of iodoacetic acid in airtight vials (ischemic treatment). 
SRIF compounds were applied for 1 h during the incubation period. All experiments were 
performed at the same time of the day (between 09:00 and 11:00 a.m.) in order to exclude possible 
circadian influences. The data were collected from both male and female WT and sst1 KO mice; the 
results were combined as there were no apparent gender differences. Experiments were performed 
in compliance with the Italian law on animal care N° 116/1992 and in accordance with the 
European Community Council Directive (EEC/609/86). All efforts were made to reduce both 
animal suffering and the number of animals used.
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TUNEL staining
At the end of the incubation period, the retinas were immersion fixed in 4% paraformaldehyde in 
0.1 M phosphate buffer (PB) for 45 to 60 min at room temperature and stored overnight in 25% 
sucrose in 0.1 M PB at 4°C. Retinal sections were cut perpendicularly to the vitreal surface at 10 
µm with a cryostat, mounted onto gelatine-coated slides and stored at -20°C. All retinas were cut 
with the same temporal-to-nasal orientation. Consecutive sections were alternately put onto a series 
of five slides, so that on each slide the sections were spaced every 50 µm. Five sections were put on 
each slide, and at least 2 series of slides (10 sections) were prepared and analysed from each retina. 
Corresponding series of sections were used in each experiment. An in situ cell death detection kit 
(Roche Diagnostics, Basel, Switzerland) was used to identify apoptotic profiles in the nuclear layers 
of the retina by TUNEL technique according to the manufacturer’s instructions. The slides were 
coverslipped in a 0.1 M PB-glycerine mixture containing 0.5 µg/ml of 4’-6-diamidino-2-
phenylindole (DAPI). To calculate an “index of cell death” (Catalani et al. 2007), images of both 
the TUNEL and the DAPI stainings were acquired with a digital photocamera (Carl Zeiss Vision 
GmbH, München-Hallbergmoos, Germany) connected to a Zeiss microscope equipped with epi-
fluorescence. The measurements were obtained with a system of computer-assisted image analysis 
using Axiovision 4 and KS-300 software (Zeiss), as previously described (Catalani et al. 2007). 
Briefly, in the outer nuclear layer (ONL) and in the inner nucleat layer (INL), both the TUNEL and 
the DAPI images relative to the same field were visualized. The areas of the ONL and of the INL in 
the DAPI image were measured. Subsequently, the TUNEL image was thresholded and the labelled 
areas in the ONL and in the INL were measured. The ratio between the area covered by the TUNEL 
staining and the area of the retinal layer seen with the DAPI counterstain was taken as an “index of 
cell death”. In the ganglion cell layer (GCL), the “index of cell death” was calculated as the ratio 
between the number of the TUNEL-labelled and that of the DAPI-stained cells. After statistics, the 
raw data (arbitrary units) from the same experiment were calculated as a percentage of the cell 
death in untreated retinas since basal values among different experiments may vary. Then, data 
belonging from different experiments were represented and averaged in the same graph.
Glutamate release
At the end of the incubation period, the vials containing supernatants of each retinas were stored at -
80°C. The rate of glutamate release was measured using HPLC electrospray tandem mass 
spectrometry (ESI-MS), according to previous studies (Catalani et al. 2007; Timperio et al. 2007). 
Briefly, the samples were lyophilised and reconstituted in 100 µl of 10% acetonitrile. For chemical 
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derivatisation, they were incubated for 30 min in darkness at 60°C in a water bath with 20 µl of 10 
M KOH and 500 µl of 0.1 mM dansyl chloride. HPLC was performed using a Beckman Model 126 
Programming Solvent Module pump chromatograph (Beckman Instruments, Brea, CA, USA). The 
chromatographic separations were carried out with Waters ODS2 Spherisorb 250 mm x 4.6 mm i.d. 
5 µm packed column (Teknokroma, Barcelona, Spain) as stationary phase, preceded by a guard 
column of Spherisorb RPC18, 5 µm, 4 mm x 4 mm. The mobile phase was double-distilled water 
0.5% formic acid (mobile phase A), and acetonitrile 0.5% formic acid (mobile phase B). ESI-MS 
was performed on an ion trap mass spectrometer (Esquire 3000 plus, Bruker Daltonik, Bremen, 
Germany) in the positive mode. For the analysis with pneumatically assisted ESI, an electrospray 
voltage of 4 kV and a Nebulizer 35 psi and Dry Gas 10 l/min were employed. The temperature of 
dry gas was set to 300°C. Full-scan spectra were acquired over the range 50-1500 m/z (scan 
duration, 1 s). After statistics, the raw data (ng/ml) from the same experiment were calculated as a 
percentage of the glutamate release in untreated retinas since basal values among different 
experiments may vary (WT: 20.29-41.27 ng/ml; sst1 KO: 21.83-38.51 ng/ml). Then, data belonging 
from different experiments were represented and averaged in the same graph.
Immunohistochemistry
Antibodies directed to sst2A isoform (Vanetti et al. 1992; Patel et al. 1993) were purchased from 
Gramsch (Gramsch Laboratories, Schwabhausen, Germany). A rabbit antiserum (cat. # SS-800) or a 
guinea pig antiserum (cat. # SS-870) were used at 1:500 and 1:5000 dilution, respectively. The 
sections were washed in 0.1 M PB and incubated overnight at 4 °C in primary antibody diluted in 
0.1 M PB containing 0.5% Triton X-100. Following washes in 0.1 M PB, the sections were 
incubated with the appropriate secondary antibody conjugated with Alexa Fluor 488 (Molecular 
Probes, Eugene, OR, USA) at a dilution of 1:200 in 0.1 M PB containing 0.5% Triton X-100 for 1 h 
at room temperature. Finally, the slides were coverslipped in a 0.1 M PB-glycerine mixture and 
observed with a Zeiss microscope equipped with epi-fluorescence. Digital images were acquired 
using a 40x plan-NEOFLUAR objective, a digital Axiocam MRC photocamera and Axiovision 4 
software (Zeiss). The digital images were optimised for contrast and brightness using Adobe 
Photoshop (Adobe Systems, Mountain View, CA, USA) and saved at a minimum of 300 dpi.
PCR experiments
Total RNA from 4 retinas for each experimental condition was extracted with the RNeasy Mini Kit 
with DNAse digestion (Qiagen, Valencia, CA, USA), according to the manufacturer’s 
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recommended procedure. After solubilization in RNase-free water, total RNA was quantified by 
Bio-Rad SmartSpec 3000 spectrophotometer (Hercules, CA, USA). First-strand cDNA was 
generated from 3 µg of total RNA using iScript cDNA Synthesis Kit (Bio-Rad). As show in Table 
1, a set of primer pairs amplifying at 102-195 bp fragment have been designed by Primer3 software 
(Rozen and Skaletsky 2000) or have been obtained from the Real Time PCR Primer and Probe 
Database, RTprimerDB (Pattyn et al. 2006) to hybridise to unique regions of the appropriate gene 
sequence. 
The reverse transcriptase (RT)-PCR reactions were carried out using 1 µl of cDNA in a 15 µl total 
volume of PCR buffer (Invitrogen, Milano, Italy), containing 3 mM MgCl2, 300 µM dNTPs, and 
300 nM of appropriate primers. Taq polymerase (0.35 U) was also added. The amplification 
reactions were carried out in a thermal gradient cycler (Bio-Rad) for 40 cycles. Each cycle consisted 
of denaturation for 30 sec at 94°C, annealing for 30 sec at 58°C, and an extension for 30 sec at 
72°C. A final extension step at 72°C for 5 min terminated the amplification. For each amplification, 
two types of controls were performed: (i) RT-PCR mixture with no reverse transcriptase to control 
for genomic DNA contamination, and (ii) PCR mixture with no cDNA template, to check for 
possible external contamination. A 5 µl sample of the PCR reaction was electrophoresed on an 
ethidium bromide-containing 2% agarose gel by the use of the Bio-Rad Sub-cell GT system. 
Real-Time RT-PCR (QPCR) was performed using SYBR Green on MiniOpticon Two-Color Real-
Time PCR detection System (Bio-Rad). The final reaction mixture contained 1 µl of cDNA, 300 
nM of each primer, 7.5 µl of iQ SYBR Green Supermix (Bio-Rad), and RNase-free water to 
complete the reaction mixture volume to 15 µl. All reactions were run as triplicates. The QPCR was 
performed with hot-start denaturation step at 95°C for 3 min, and then was carried out for 40 cycles 
at 95°C for 10 sec and 58° for 20 sec. The fluorescence was read during the reaction by the Opticon 
Monitor 3 software (Bio-Rad), allowing a continuous monitoring of the amount of PCR products. 
Primers have been initially used to generate a standard curve over a large dynamic range of starting 
cDNA quantity which allows to calculate the amplification efficiency (a critical value for the 
correct quantification of expression data) for each of the primer pairs (Table 1). The melt-curve 
analysis was performed at the end of each experiment to verify that a single product per primer pair 
was amplified (data not shown). As to control experiments, gel electrophoresis was also performed 
to verify the sizes of the amplified QPCR products. RPL13a, a stable mRNA during ischemia (Tian 
et al. 2007), was used in our experiments as an internal standard. As previously described, samples 
were compared using the relative cycle threshold (CT) method (Livak and Schmittgen 2001). The 
fold increase or decrease was determined relative to a control after normalizing to ribosomal protein 
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L13a (RPL13a) (internal standard). The formula 2-CT was used, where CT is: (gene of interest 
CT) - (RPL13a CT), and CT is (CT experimental) - (CT control). After statistics, data 
belonging from different experiments were represented and averaged in the same graph.
Statistics
Upon verification of normal distribution, statistical significance of raw data between the groups in 
each experiment was evaluated using unpaired Student’s t-test or ANOVA followed by multiple 
comparison Newman-Keuls Multiple Comparison post-test. The GraphPad Prism software package 
(Graph Software, San Diego, CA, USA) was used. The results were expressed as means ± SEM of 
the indicated n values.
Chemicals
SRIF (SRIF-14) was purchased from Bachem (Bubendorf, Switzerland). Octreotide (also known as 
SMS 201-995 or sandostatin), pasireotid  (also known as SOM230) and cyanamide (D-Tyr8
cyanamide 154806) were a gift of Prof. D. Hoyer and Dr. H. Schmid (Novartis Pharma, Basel, 
Switzerland). CH-275 (Weckbecker et al. 2003) was purchased from NeoMPS (Strasbourg, 
France). Acetonitrile and Taq polymerase were purchased from Carlo Erba (Milano, Italy) and 
Invitrogen, respectively. The forward and reverse primers as well as agarose were purchased from 
Eurobio (Les Ulis, France). Where not specified, chemicals and reagents were obtained from 
Sigma-Aldrich (St. Louis, MO, USA).
Results
Effects of SRIF compounds on ischemia-induced cell death
All compounds were applied for 1 h at 1 µM, a concentration giving maximal receptor occupancy in 
different systems (Weckbecker et al. 2003; Cervia et al. 2005), including mouse and rat retina 
(Bigiani et al. 2004; Pavan et al. 2004; Mastrodimou et al. 2005; Mastrodimou et al. 2006a; 
Mastrodimou et al. 2006b; Mastrodimou et al. 2008). As shown in Fig. 1 and 2, treatments with 
SRIF, pasireotide or octreotide resulted in overall protection of WT ischemic retinas. In particular, 
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SRIF, pasireotide and octreotide decreased the index of cell death calculated with the TUNEL 
staining in the ONL of WT ischemic retinas by 38 ± 5%, 39 ± 6% and 28 ± 3%, respectively. 
Similarly, pasireotide and octreotide, but not SRIF, decreased the index of cell death in the INL (by 
40 ± 4% and 33 ± 5%, respectively) and in the GCL (by 18 ± 3% and 38 ± 6%, respectively) of WT 
ischemic retinas. In contrast to our expectations, however, treatments with SRIF, pasireotide or 
octreotide resulted in significant increases of the index of cell death in sst1 KO ischemic retinas. 
Indeed, SRIF, pasireotide and octreotide increased the index of cell death in the ONL (by 34 ± 6%, 
74 ± 15% and 68 ± 10%, respectively), in the INL (by 122 ± 14%, 52 ± 11% and 73 ± 17%, 
respectively), and in the GCL (by 159 ± 40%, 214 ± 86% and 184 ± 42%, respectively) of sst1 KO 
ischemic retinas. The administration of the sst2 antagonist cyanamide had comparable effects in 
both strains. In particular, it increased the index of cell death in the ONL, INL and GCL by 40 ± 
20%, 102 ± 33% and 199 ± 27%, respectively, in the WT ischemic retinas and by 92 ± 12%, 65 ± 
17% and 71 ± 32%, respectively, in the sst1 KO ischemic retinas.
SRIF, pasireotide or octreotide at a concentration of 10 nM (1 h) did not affect the index of cell 
death either in WT or in sst1 KO ischemic retinas (n = 3, data not shown). This observation seems to 
exclude the possibility of protective effects of low agonist concentrations in sst1 KO mice. In 
addition, as shown in Fig. 3, no apparent variations in the TUNEL staining were detected in the 
absence or in the presence of the sst1 agonist CH-275 (1 h at 1 µM) in WT ischemic retinas, thus 
excluding a major role of sst1 in our system, in agreement with recent results in the rat retina 
(Kiagiadaki and Thermos 2008).
Effects of octreotide on ischemia-induced glutamate release
We have previously demonstrated that glutamate release significantly increases in WT retinas 
incubated in the ischemic solution and that this increase is significantly reduced, in parallel with the 
index of cell death, in sst1 KO retinas (Catalani et al. 2007). Similarly, in the present study, we 
observed that the rates of glutamate release paralleled the changes of the index of cell death 
following treatment with a sst2 agonist. Indeed, octreotide (1 h at 1 µM) decreased glutamate release 
in ischemic WT retinas by 22 ± 3%, while it increased glutamate release in ischemic sst1 KO retinas
by 45 ± 14% (Fig. 4).
sst2-ligand complex internalisation during ischemia
The observations of increased ischemic damage and glutamate release in sst1 KO ischemic retinas 
in the presence of SRIF, pasireotide and/or octreotide may be explained by sst2 desensitisation, 
possibly through the endocytosis of plasma membrane sst2-ligand complex in retinal cells. We 
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therefore tested possible ligand-mediated sst2 internalisation in cells of WT or sst1 KO ischemic 
retina, by means of sst2A immunofluorescence. In both WT and sst1 KO control retinas, the pattern 
of sst2A immunostaining was consistent with that described previously (Cristiani et al. 2002; Casini
et al. 2004). As recently reported by us (Catalani et al. 2007), after 1 h ischemia sst2A
immunofluorescence was reduced in rod bipolar cells, however this reduction was less pronounced 
in sst1 KO than in WT retinas (Fig. 5A-D). For this analysis we only concentrated on sst2A
expressing amacrine cells; indeed, sst2A immunostaining in amacrine cells did not appear to be 
affected by 1 h ischemic treatment either in WT or in sst1 KO retinas. As shown in Fig. 5E-H, both 
large and small amacrine cell somata were labelled at or near their plasma membrane. In addition,
some sst2A immunostaining was also observed in the cytoplasm of large-sized amacrine cell bodies, 
but no differences were observed between untreated and octreotide-treated ischemic retinas (1 h at 1 
µM), either in the WT or in the sst1 KO animals.
Effects of octreotide on GPCR regulatory proteins during ischemia
The desensitisation of the sst2-agonist complex in sst1 KO retinas may occur through a reduced 
coupling efficiency between cell surface receptors and the intracellular signalling machinery. For 
instance, GPCR regulatory proteins may induce the inhibition of signalling when sst2 is 
continuously occupied by the agonist. To substantiate this hypothesis, we first investigated the 
expression of: i) GPCR kinases (GRKs, including GRK1 and GRK2) and, ii) regulators of G protein 
signalling (RGSs, including RGS1, RGS2, RGS5 and RGS9). As shown in Fig. 6A, by means of 
RT-PCR, we found that GRK1, GRK2, RGS1, RGS2, RGS5 and RGS9 mRNAs are indeed 
expressed in the mouse retina. Then, in another set of experiments, QPCR using SYBR Green 
chemistry was used to quantify the relative levels of these mRNAs in different models/experimental 
conditions. As shown in Fig. 6B, GRK1, GRK2, RGS1, RGS2, RGS5 and RGS9 mRNAs were 
similarly expressed in retinas of WT and sst1 KO mice. In addition, the incubation of WT retinas in 
the ischemic solution elicited a marked induction of GRK1 and RGS1 mRNA levels, being 18 ± 7-
and 33 ± 7-fold enriched, respectively, with respect to non ischemic retinas (Fig. 6C). The 
incubation of sst1 KO retinas in the ischemic solution caused a limited increase of GRK1 and RGS1 
mRNA levels by 2.0 ± 0.06- and 2.8 ± 0.06-fold, respectively (Fig. 6D). In contrast, ischemic 
treatment did not change the mRNA levels of GRK2, RGS2, RGS5 and RGS9 in both WT and sst1
KO retinas. Finally, we investigated the mRNA levels of the two isoforms responding to ischemia 
(GRK1 and RGS1) in ischemic retinas treated with octreotide (1 h at 1 µM). In ischemic retinas of 
WT mice, octreotide decreased by 47 ± 5% and 70 ± 5% the mRNA levels of GRK1 and RGS1, 
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respectively. In contrast, in ischemic retinas of sst1 KO mice, while octreotide decreased by 74 ± 
7% the mRNA levels of GRK1, it did not affect the mRNA levels of RGS1 (Fig. 7).
Discussion
Among pharmacological targets for the treatment of ischemia-based retinal diseases, the SRIF 
system is a candidate that is being subjected to intensive investigation (Cervia et al. 2008). In the 
present study, we demonstrated that the pharmacological activation of SRIF receptors expressed in 
retinas of WT mice protects against ischemia. In particular, SRIF application decreased cell death in 
the ONL, although no effects of SRIF were observed in the INL and GCL. The only partial effect of 
SRIF can be easily explained taking into account that the native peptide is likely to be subjected to 
rapid enzymatic degradation and subsequent poor access to the retina of mouse, as previously 
suggested in the rat retina (Mastrodimou et al. 2005; Kiagiadaki and Thermos 2008). On the other 
hand, we cannot exclude that other factors may influence SRIF’s action (i.e., absorption). The 
powerful activity of SRIF in all retinal layers of sst1 KO mice is probably due to the over-
expression of sst2, an event that affects the ligand efficacy.
Because of their long-acting properties both in vitro and in vivo, low molecular 
weight/metabolically stable compounds are more suitable for clinical application or experimental 
investigations than SRIF (Weckbecker et al. 2003; Cervia and Bagnoli 2007). Consistently, we 
showed that in WT ischemic retinas both the multireceptor ligand pasireotide and the sst2-preferring 
agonist octreotide decreased cell death in all retinal layers, suggesting that SRIF receptor activation 
in the retina can be strongly influenced by the ligand used, in agreement with results obtained in 
different systems (Siehler and Hoyer 1999a, b; Giannetti et al. 2000; Cervia et al. 2003a; Cervia et 
al. 2003b; Cervia et al. 2003c; Nunn et al. 2004; Tulipano and Schulz 2007). In addition, the 
observations that pasireotide effects (and its efficacy) were mimicked by the selective activation of 
sst2 (by octreotide), but not of sst1 (by CH-275), and that the selective blocking of sst2 (by 
cyanamide) increased cell death are consistent with a major role of sst2 against retinal ischemia in 
mice. This conclusion is also supported by previous data reporting that octreotide protects against 
ischemia-reperfusion injury in guinea pig retinas (Celiker and Ilhan 2002) and that different sst2
agonists (including octreotide) attenuate cell death in an in vitro model of the ischemic rat retina
(Mastrodimou et al. 2005; Mastrodimou et al. 2008).
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We have observed that, at nanomolar concentrations octreotide is not active in mouse ischemic 
retinas. Accordingly, in the rat retina, sst2 agonists have been recently demonstrated to be 
neuroprotective in a micromolar dose-dependent manner (Kiagiadaki and Thermos 2008). It is 
important to note that, at the concentration of 1 µM (used in the present work), octreotide may be 
active on SRIF receptors other than sst2, i.e., sst3 and sst5, according to its affinity values in vitro
(Cervia et al. 2005). Although it is difficult to conjecture about the actual drug concentration 
reaching the retina (likely much smaller than that administered in the incubation solution), we 
cannot completely exclude an involvement of sst3 and/or sst5 in the observed effects. On the other 
hand, evidence of sst3 and sst5 presence/localization in the retina are still elusive (Cervia et al.
2008). In addition, selective agonists for sst3 and sst5 have been previously found to elicit no effects 
in the mouse retina (Pavan et al. 2004). In contrast, the expression and the localisation of sst2 have 
been extensively demonstrated in a variety of retinal cell populations of mammals (Thermos 2003; 
Casini et al. 2005; Cervia et al. 2008). In particular, in the mouse retina, sst2A immunoreactivity has 
been reported in rod bipolar cells, horizontal cells, and in amacrine cells, including glycinergic 
amacrine cells and the population of tyrosine hydroxylase-containing, dopaminergic amacrine cells 
(Cristiani et al. 2002; Casini et al. 2004). Functionally, in mouse retinal explants, sst2 has been 
shown to inhibit K+-induced glutamate release (Dal Monte et al. 2003a), and in general a prominent 
role of sst2 in the retina involves the regulation of glutamate release (Cervia et al. 2008). This 
function is likely to represent an important contribution to the regulation of the glutamatergic 
transmission along the vertical retinal visual pathway. By limiting the amount of glutamate 
available to glutamate receptors, sst2 may also exert an important neuroprotective function against 
glutamate neurotoxicity that characterises many retinal diseases, including ischemic retinal injury 
(Osborne et al. 2004). Consistently, the SRIF-induced inhibition of glutamate release is 
significantly stronger when sst2 is over-expressed, as in sst1 KO retinas (Bigiani et al. 2004), and 
ischemic sst1 KO retinas display a marked reduction of both cell death and glutamate release with 
respect to WT retinas (Catalani et al. 2007). In agreement with these observations, in the present 
study we found that sst2 activation decreases glutamate release in ischemic WT retinas.
As previously suggested (Bigiani et al. 2004; Cammalleri et al. 2004; Pavan et al. 2004; 
Cammalleri et al. 2006), the density of sst2 may represent a rate-limiting factor for the sst2-mediated 
functions, and sst2 over-expression may overcome this limitation. This interpretation may also help 
to explain the fact that, in untreated sst1 KO ischemic retinas, a protective activity occurred (present 
results; Catalani et al. 2007) indicating that a critical concentration of active sst2 for the creation of 
protective effects against ischemia can result from an increase in the number of expressed receptors 
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(as in the sst1 KO retinas). In addition, the fact that sst2 blocking results in the reversal of sst2
protective effects suggests a constitutive activity of the receptor under ischemic conditions. In 
agreement with our hypothesis, a recombinant truncated form of the rat sst2 has been previously 
shown to display agonist-independent, constitutive activity (Schwartkop et al. 1999) and 
constitutive activation of sst2 has been recently demonstrated in mouse pituitary corticotroph cells 
(Ben-Shlomo et al. 2007).
Surprisingly, we observed that in sst1 KO retinas the pharmacological activation of SRIF receptors 
under ischemic conditions does not protect the retina, but instead it increases both cell death and 
glutamate release: both the pharmacological activation (agonism) and blocking (antagonism) of sst2
exert similar functional effects. These results are not in line with our expectation of ameliorating 
effects of octreotide in retinas over-expressing sst2 (as the sst1 KO retinas) as compared to WT 
retinas. The simplest explanation for this effect is that in sst1 KO retinas sst2 may be rapidly 
desensitised by agonists, thus resulting in a decrease of its functional activity. For instance, 
desensitisation may involve a loss of plasma membrane sst2 due to receptor endocytosis. Indeed, 
there is a general agreement that, in a variety of differentiated cells and in model cell lines, as well 
as in tissues samples, interactions of SRIF agonists with sst2 (after a few minutes of agonist 
exposure) may result in internalisation of receptor-agonist complexes (Sarret et al. 1999; Petrucci et 
al. 2000; Stroh et al. 2000; Csaba et al. 2001; Csaba et al. 2002; Elberg et al. 2002; Csaba et al.
2003; Hofland and Lamberts 2003; Liu et al. 2005; Cescato et al. 2006; Csaba et al. 2007; Duran-
Prado et al. 2007; Liu et al. 2008). In our system, the consequence of such internalisation would be 
a decrease of available sst2 on cell membranes of sst1 KO retinas and reversal of the anti-ischemic 
effect. However, our data are not consistent with this possibility since we demonstrated that sst2 was 
not internalised as a consequence of the treatment with octreotide. Alternatively, desensitisation of 
the sst2-agonist complex in sst1 KO retinas may occur through a reduced coupling efficiency 
between cell surface receptors and the intracellular signalling machinery. In this respect, recent 
results in recombinant systems demonstrate the occurrence of sst2 uncoupling through receptor 
phosphorylation distinct from sst2 internalisation (Liu et al. 2008). GRKs are key participants in the 
pathways leading to phosphorylation of serine/threonine residues in many different types of ligand-
occupied GPCR. The phosphorylation of GPCRs by GRKs promotes receptor desensitisation 
through the uncoupling of GPCRs from G proteins as well as through the modulation of 
intracellular signalling cascades (Moore et al. 2007; Ribas et al. 2007). In addition to GRKs, RGSs 
have been also found to regulate GPCR responses by binding to and stimulating the GTPase activity 
of the receptor-activated GTP-bound G (Jean-Baptiste et al. 2006). Previous results demonstrated 
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the presence of GRK1 and RGS9 in the mouse retina (Weiss et al. 2001; Krispel et al. 2006; Song 
et al. 2007). In addition, GRK2 was detected in the chicken retina (de Almeida Gomes and Ventura 
2004). In this paper, we have demonstrated that GRK1, GRK2, RGS1, RGS2, RGS5 and RGS9 are 
all expressed in the retina, with no difference among WT and sst1 KO mice. In addition, only the 
expression of GRK1 and RGS1 is increased by retinal ischemic damage but with much more 
efficacy in WT mice than in sst1 KO mice. These results indicate that low levels of these proteins 
correlate with the protective effects exerted by sst2, as for instance in untreated sst1 KO retinas. In 
line with this finding we also found that sst2 agonism in WT retinas down-regulates both GRK1 and 
RGS1 probably unmasking sst2 protective effects against ischemic damage. If that is the case, the 
fact that the activation of over-expressed sst2 (as in sst1 KO retinas) did not affect RGS1 levels may 
explain the desensitisation of sst2-agonist complex: sst2 is occupied by the agonists but its protective 
functions are inhibited by its uncoupling to RGS1 inhibition, thus resulting in the observed 
detrimental effects of sst2 agonism on ischemia. The existence of possible interactions between 
GRKs/RGSs, including RGS1, and SRIF receptors (Kong et al. 2002; Young Shim et al. 2006)
suggests that coordinate regulation of SRIF system and these GPCR regulatory proteins may occur. 
Conclusion
The results of the present study confirm and expand previous observations suggesting important 
protective actions exerted by SRIF acting at the sst2 against retinal ischemia. Together, these data 
constitute a solid background for SRIF-based therapies of retinal diseases in the future. In 
particular, in WT mouse retinas, sst2 agonism resulted in a protective effects against ischemia while 
sst2 antagonism had a detrimental effect. On the other hand, the investigation of the functional role 
of the over-expressed sst2 in sst1 KO retinas appears to be more complex than expected, since both 
the activation and the blocking of sst2 had detrimental effects on ischemia. Our hypothesis is that 
the desensitisation of the sst2-agonist complex in sst1 KO retinas occurs through a reduced coupling 
efficiency between cell surface receptors and the intracellular signalling machinery. In different 
systems, including the retina, many mechanisms are involved in the amplification occurring in the 
signalling cascade of SRIF receptors (Cervia and Bagnoli 2007; Cervia et al. 2008). However, 
whether sst2 expressed in WT or sst1 KO retinas are coupled to different machineries of signalling 
mechanisms during ischemia, and the possibile implications in pharmacological/clinical studies, 
needs to be further investigated.
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Table 1 Primers used for PCR analysis
a
 as calculated by the Opticon Monitor 3 software (Bio-Rad)
Gene Primer sequence product length (bp)
QPCR: 
amplification 
efficiencya
Gene Bank 
Accession No.
RPL13a F: 5’-cactctggaggagaaacggaagg-3’R: 5’-gcaggcatgaggcaaacagtc-3’ 182 96.7% NM_009438
GRK1 F: 5’-ttgacaaagcggacacagag-3’R: 5’-tggtgattcccttcatgtca-3’ 153 96.0% NM_011881
GRK2 F: 5’-gccatggagaagagcaagac-3’R: 5’-cactgcttccccaatttcat-3’ 195 96.8% NM_177078
RGS1 F: 5’-gccaaagacttttggaatgg-3’R: 5’-tggttggcaaggagtttttc-3’ 153 99.2% NM_015811
RGS2 F: 5’-gctacatgagaccaggagtc-3’R: 5’-cctaggttgctgacttcctg-3’ 187 95.6% NM_009061
RGS5 F: 5’-cggagaaggcaaagcaaat-3’R: 5’-ccaggttcttcatggtgatgt-3’ 102 100.0% NM_009063
RGS9 F: 5’-gaggatggcatttctccaaa-3’R: 5’-ggttctgtgcctccaggtta-3’ 182 99.5% NM_011268
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Legends
Fig. 1. TUNEL staining in non ischemic (control) or ischemic retinas of WT (A-D) and sst1 KO (E-
H) mice. The ischemic treatment was performed in the absence or in the presence of octreotide 
(OCT) or cyanamide (CYN) (1 h at 1 µM). Each panel is representative of 10 sections from 8 
retinas (independent experiments). Calibration bar: 20 µm.
Fig. 2. Cell death in ischemic retinas of WT and sst1 KO mice. Quantitative evaluation of cell death
in the ONL (A), INL (B) and GCL (C) after ischemic treatment in the presence of different SRIF 
compounds (1 h at 1 µM). In the ONL and INL, the ratio between the area covered by the TUNEL 
staining and the area of the retinal layer seen with the DAPI counterstain was taken as an “index of 
cell death”. In the GCL, the “index of cell death” was calculated as the ratio between the number of 
the TUNEL-labelled and that of the DAPI-stained cells. After statistics, the raw data (arbitrary 
units) from the same experiment were calculated as a percentage of the cell death in untreated 
retinas since basal values among different experiments may vary. Then, data belonging from 
different experiments have been represented and averaged in the same graph. Each histogram 
represents the mean ± SEM of data from 8 retinas (independent experiments). *p < 0.05 vs the 
respective control values (i.e., untreated WT or sst1 KO ischemic retinas) set as the 100% (ANOVA
followed by Newman-Keuls post test on raw data).
Fig 3. Representative TUNEL staining in untreated WT ischemic retinas (A) or in WT ischemic 
retinas treated with CH-275 (1 h at 1 µM) (B). Calibration bar: 20 µm.
Fig 4. Glutamate release in retinas of WT and sst1 KO mice after ischemic treatment in the presence 
of octreotide (1 h at 1 µM). After statistics, the raw data (ng/ml) from the same experiment were 
calculated as a percentage of the glutamate release in untreated retinas since basal values among 
different experiments may vary (WT: 20.29-41.27 ng/ml; sst1 KO: 21.83-38.51 ng/ml). Then, data 
belonging from different experiments have been represented and averaged in the same graph. Each 
histogram represents the mean ± SEM of data from 6-7 retinas (independent experiments). *p < 
0.05 vs the respective control values (i.e., untreated WT or sst1 KO ischemic retinas) set as the 
100% (ANOVA followed by Newman-Keuls post test on raw data). 
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Fig 5. A-D: sst2A immunostaining patterns in WT and sst1 KO retinas in control or in ischemic 
conditions. E-H: sst2A immunostaining in retinas of WT and sst1 KO mice after ischemic treatment 
in the absence or in the presence of octreotide (1 h at 1 µM). Each panel is representative of 8 
retinas (independent experiments). In all cases, large-sized sst2 immunostained amacrine cells 
displayed some immunoreactivity inside their cell bodies, while the small-sized sst2 immunostained 
amacrine cells (insets) were only labelled at or near their plasma membrane. Calibration bars: 20 
µm.
Fig 6. Expression levels of GPCR regulatory proteins in mouse retina. (A) RT-PCR products of 
RPL13a and of different GRKs/RGSs in WT retinas. The panel is representative of 3 independent 
experiments. QPCR evaluation of different GRKs/RGSs in WT and sst1 KO non ischemic retinas
(B), in WT non ischemic and ischemic retinas (C) and, in sst1 KO non ischemic and ischemic 
retinas (D). Data were analysed by the formula 2-CT using RPL13a as internal standard. Each 
histogram represents the mean ± SEM of data from 3 independent experiments. *p < 0.05 vs the 
respective control values (i.e., WT or sst1 KO non ischemic) (ANOVA followed by Newman-Keuls 
post test on raw data). 
Fig 7. QPCR evaluation of GRK1 (A) and RGS1 (B) in WT and sst1 KO retinas after ischemic 
treatment both in the absence and in the presence of octreotide (1 h at 1 µM). Data were analysed by
the formula 2-CT using RPL13a as internal standard. Each histogram represents the mean ± SEM 
of data from 3 independent experiments. *p < 0.05 vs the respective control values (i.e., untreated 
WT or sst1 KO ischemic retinas) (unpaired Student’s t-test on raw data). 
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